001     294462
005     20241222014504.0
024 7 _ |a 10.1038/s44318-024-00295-y
|2 doi
024 7 _ |a pmid:39543396
|2 pmid
024 7 _ |a 0261-4189
|2 ISSN
024 7 _ |a 1460-2075
|2 ISSN
024 7 _ |a altmetric:170877733
|2 altmetric
037 _ _ |a DKFZ-2024-02287
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Bender, Alexander
|b 0
245 _ _ |a Redistribution of PU.1 partner transcription factor RUNX1 binding secures cell survival during leukemogenesis.
260 _ _ |a Hoboken, NJ [u.a.]
|c 2024
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1734445626_4133
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Dec;43(24):6291-6309
520 _ _ |a Transcription factors (TFs) orchestrating lineage-development often control genes required for cellular survival. However, it is not well understood how cells survive when such TFs are lost, for example in cancer. PU.1 is an essential TF for myeloid fate, and mice with downregulated PU.1 levels develop acute myeloid leukemia (AML). Combining a multi-omics approach with a functional genetic screen, we reveal that PU.1-downregulated cells fundamentally change their survival control from cytokine-driven pathways to overexpression of an autophagy-predominated stem cell gene program, for which we also find evidence in human AML. Control of this program involves redirected chromatin occupancy of the PU.1 partner TF Runx1 to a lineage-inappropriate binding site repertoire. Hence, genomic reallocation of TF binding upon loss of a partner TF can act as a pro-oncogenic failsafe mechanism by sustaining cell survival during leukemogenesis.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Myeloid Development
|2 Other
650 _ 7 |a Myeloid Leukemia
|2 Other
650 _ 7 |a PU.1
|2 Other
650 _ 7 |a RUNX1
|2 Other
700 1 _ |a Boydere, Füsun
|b 1
700 1 _ |a Jayavelu, Ashok Kumar
|0 P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af
|b 2
|u dkfz
700 1 _ |a Tibello, Alessia
|b 3
700 1 _ |a König, Thorsten
|b 4
700 1 _ |a Aleth, Hanna
|b 5
700 1 _ |a Meyer Zu Hörste, Gerd
|b 6
700 1 _ |a Vogl, Thomas
|b 7
700 1 _ |a Rosenbauer, Frank
|0 0000-0001-7977-9421
|b 8
773 _ _ |a 10.1038/s44318-024-00295-y
|0 PERI:(DE-600)1467419-1
|n 24
|p 6291-6309
|t The EMBO journal
|v 43
|y 2024
|x 0261-4189
909 C O |p VDB
|o oai:inrepo02.dkfz.de:294462
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)1546aa03aab6491ab3cf01f75ac2b6af
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-08-24
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EMBO J : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-24
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EMBO J : 2022
|d 2023-08-24
920 1 _ |0 I:(DE-He78)A400-20160331
|k A400
|l KKE Pädiatrische Leukämie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A400-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21